Zhang et al. (2021) reported that oxyepiberberine inhibited the development and progress of non-small cell lung cancer (NSCLC) using the combination of network pharmacology and biological experiment. Yuan et al. (2021) found that scopoletin against NSCLC through the pathways of RAS-RAF-MEK-ERK and PI3K/AKT via the combination of network pharmacology and molecular docking. So, we hypothesized that the combination of network pharmacology, molecular docking, and in vitro bio-experiment will be a powerful tool to systematically investigate the pharmacological actions of CUR against TNBC. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.